Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Observational Study Comparing Chemotherapy Plus Pembrolizumab Versus Nivolumab Plus Ipilimumab With Chemotherapy in Patients With Metastatic Non-Small Cell Lung Cancer and PD-L1 Expression Below 50%

NCT07394062 is registered in ClinicalTrials.gov with Gazi University as lead sponsor.

NCT NCT07394062
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07394062 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Observational Study Comparing Chemotherapy Plus Pembrolizumab Versus Nivolumab Plus Ipilimumab With Chemotherapy in Patients With Metastatic Non-Small Cell Lung Cancer and PD-L1 Expression Below 50%
Lead sponsor
Gazi University
Phase
Observational
Overall status
Recruiting
Start date
February 1, 2026
Completion date
February 29, 2028
Enrollment
400 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic nonsmall cell lung cancer, nonsmall cell lung cancer, stage iv